Premium
Retracted: Randomised controlled trial of the use of human chorionic gonadotrophin in recurrent miscarriage associated with polycystic ovaries
Author(s) -
Malcolm Pearce J.,
Hamid Rosol I.
Publication year - 1994
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1994.tb13185.x
Subject(s) - medicine , polycystic ovary , miscarriage , placebo , gynecology , pregnancy , pregnancy rate , polycystic ovarian disease , obstetrics , ovulation induction , ovulation , human chorionic gonadotropin , hormone , insulin resistance , alternative medicine , pathology , biology , insulin , genetics
ABSTRACT Objective To determine whether the use of human chorionic gonadotrophin (hCG) would reduce the recurrent miscarriage rate in women with polycystic ovarian disease. Design Double‐blind, prospective, randomised controlled trial. Setting A pregnancy loss clinic in a London teaching hospital. Subjects One hundred and ninety‐one women with a history of three consecutive spontaneous first trimester miscarriages and polycystic ovary syndrome. Intervention 10000 i.u. of hCG or a placebo were given when the leading follicle was ≥ 21 ram, then 5000 i.u. of hCG or a placebo were given twice weekly until miscarriage or the tenth week of pregnancy. Main outcome measure Miscarriage rate. Results Women with polycystic ovaries who received hCG treatment had a lower miscarriage rate (14%) compared with women who received placebo (43%). In women with follicular phase luteinising hormone ≥ 10 iu/1, those who received hCG therapy had a miscarriage rate of 10% compared with a rate of 44% in women who received the placebo. When clomiphene was used for ovulation induction, women treated with hCG had a miscarriage rate of 14% compared with a rate 47 % in women who received the placebo. There was no significant benefit from hCG therapy in natural cycles. Conclusion The use of hCG in women with recurrent miscarriage and polycystic ovary syndrome improves the pregnancy outcome.